Daniel B. Ravicher provides intellectual property and technology related litigation and transactional advice to clients.
Daniel's litigation experience includes representing rights holders and accused infringers in patent and copyright infringement actions related to various types of technology, including pharmaceuticals, biotechnology, medical devices, software, mobile apps and transportation. He represented the successful plaintiffs in the Association for Molecular Pathology v Myriad Genetics Supreme Court case that ruled human genes cannot be patented. He also successfully challenged patents on human stem cells, AIDS drugs, Internet standards, open source software, and other technologies, both in Federal Court and through proceedings at the U.S. Patent & Trademark Office. Daniel represented the plaintiffs in the Organic Seed v Monsanto case challenging patents on genetically modified seed, defended clients from various patent trolls, pursued pharmaceutical and consumer products companies for violating consumer protection statutes, and authored several briefs to the Supreme Court, the Court of Appeals for the Federal Circuit, and various other courts on issues of patent and technology law.
Daniel's transactional experience includes providing both investor side and company side representation in technology, financing and exit transactions. He has assisted clients with angel funding, venture capital financing, mergers and acquisitions, and initial public offerings, negotiated sales and licenses of patents, copyrights, and other intellectual property assets, and advised on intellectual property infringement, validity and valuation issues. A registered patent attorney, Daniel has also prosecuted patent applications and trademark and copyright registrations for clients.
Daniel was named one of 'The 50 Most Influential People in IP' by Managing Intellectual Property and Appellate Lawyer of the Week by the National Law Journal. He appeared as a guest on the PBS NewsHour and has been quoted by the Wall Street Journal, the New York Times, the Financial Times and countless other publications. He has presented at dozens of conferences and public events on issues relating to intellectual property and technology law, including being an invited witness by Congress twice on the topic of patent reform and consulting with the United Nations on patent issues impacting access to essential medicines.
Prior to Zeisler PLLC, Daniel directed the Public Patent Foundation, a not-for-profit patent reform organization he founded with support from the Rockefeller Foundation, the Nathan Cummings Foundation, the Open Society Foundation, and the Echoing Green Foundation, amongst others. He was previously associated with Brobeck, Phleger & Harrison LLP, and Patterson Belknap LLP, both in New York. Daniel also started his own solo practice and is currently a member of the faculty at the University of Miami School of Law and was previously a member of the faculty of the Benjamin N. Cardozo School of Law.
Daniel received his law degree from the University of Virginia School of Law, where he was the Franklin O'Blechman Scholar of his class, a Mortimer Caplin Public Service Award recipient and an Editor of the Virginia Journal of Law and Technology, and his bachelors degree in materials science magna cum laude with University Honors from the University of South Florida.